Table 4 Cox regression analysis for association between stages of QTc prolongation and adverse events

Diabetes

Yes VS No

0.96

(0.60,1.54)

0.862

0.72

(0.16,3.32)

0.677

0.94

(0.55,1.63)

0.836

1.06

(0.64,1.77)

0.822

0.70

(0.31,1,59)

0.392

On TKIs

Yes VS No

1.22

(0.83,1.80)

0.304

4.96

(1.35,18.29)

0.016

0.70

(0.45,1.10)

0.121

0.73

(0.47,1.11)

0.138

1.76

(0.74,4.15)

0.200

QTc Prolongation at 1st Visit

≥ 450 VS < 450

1.26

(0.84,1.89)

0.259

1.35

(0.43,4.18)

0.609

2.12

(1.36,3.32)

0.001

1.78

(1.16,2.73)

0.009

1.07

(0.47,2.44)

0.872

480–499 vs. 450–479

1.56

(0.67,3.63)

0.630

0.001

(0.001,999)

0.943

0.26

(0.08,0.81)

0.031

1.31

(0.55,3.12)

0.864

2.28

(0.51,10.19)

0.396

≥ 500 vs. 450–479

1.56

(0.54,4.51)

0.681

4.62

(0.71,30.12)

0.931

0.94

(0.32,2.79)

0.304

2.03

(0.70,5.89)

0.296

1.27

(0.14,11.61)

0.873

QTc Prolongation at 2nd Visit

≥ 450 VS < 450

1.83

(1.21,2.77)

0.004

2.98

(0.65,13.62)

0.159

2.94

(1.73,5.00)

0.001

2.56

(1.58,4.17)

0.001

1.27

(0.54,2.98))

0.577

480–499 vs. 450–479

1.98

(1.00,3.92)

0.124

0.39

(0.05,3.23)

0.739

1.06

(0.47,2.39)

0.224

0.98

(0.47,2.04)

0.466

0.81

(0.16,3.93)

0.572

≥ 500 vs. 450–479

1.42

(0.85,2.36)

0.968

0.32

(0.07,1.53)

0.449

2.89

(1.67,5.01)

0.003

1.60

(0.95,2.70)

0.08

1.53

(0.57,4.12)

0.314